Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) is a global biopharmaceutical company focused on innovative research and development of proprietary drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. Sucampo has a marketed product - AMITIZA® - and a pipeline including lifecycle management and clinical development programs. Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the United Kingdom.

Company Growth (employees)
Type
Public
HQ
Rockville, US
Founded
1996
Size (employees)
139 (est)-12%
Sucampo Pharmaceuticals was founded in 1996 and is headquartered in Rockville, US

Sucampo Pharmaceuticals Office Locations

Sucampo Pharmaceuticals has offices in Rockville, Milton, Zug, Kita Ward and in 3 other locations
Rockville, US (HQ)
550 805 King Farm Blvd
Sanda-shi, JP
4-1 Techno-Park
Chuo Ward, JP
Kobe Hybrid Business Center, 3rd Floor 6-7-6 Minatojima Minamimachi, Chuo-ku, Kobe City
Chiyoda, JP
NBF Hibiya Building, 10th Floor 1-1-7 Uchisaiwaicho
Kita Ward, JP
Nishiumeda MID Building, 4th Floor 2-2-16 Sonezakishinchi
Zug, CH
22 Baarerstrasse
Milton, GB
99 Park Drive Milton Park, Abingdon, Oxfordshire

Sucampo Pharmaceuticals Metrics

Sucampo Pharmaceuticals Financial Metrics

Revenue (2016)

$230.1 m

Revenue growth (2015-16), %

50%

Gross profit

$154.1 m

Gross profit margin (2016), %

67%

Net income (2016)

$18.5 m

Market capitalization (21-Mar-2017)

$463.4 m

Closing share price (21-Mar-2017)

$10.9

Cash (31-Dec-2016)

$198.3 m
Sucampo Pharmaceuticals's current market capitalization is $463.4 m.
Sucampo Pharmaceuticals's revenue was reported to be $230.1 m in FY, 2016 which is a 50.2% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$89.6 m$115.5 m$153.2 m$230.1 m

Revenue growth, %

29%33%50%

Cost of goods sold

$12.4 m$16.3 m$36.7 m$76 m

Gross profit

$77.2 m$99.2 m$116.4 m$154.1 m

Gross profit Margin, %

86%86%76%67%

Operating expense total

$68 m$72 m$72 m$176.2 m

EBIT

$9.2 m$27.2 m$44.5 m$53.9 m

EBIT margin, %

10%24%29%23%

Interest expense

$1.9 m$1.5 m$6.9 m$23.8 m

Interest income

$124 k$172 k$181 k$72 k

Pre tax profit

$10.3 m$27.1 m$43.7 m$14.4 m

Income tax expense

($3.9 m)($14 m)($10.3 m)$4.1 m

Net Income

$6.4 m$13.1 m$33.4 m$18.5 m
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$44.1 m$71.6 m$108.3 m$198.3 m

Accounts Receivable

$5.4 m$5.3 m$22.8 m$43 m

Inventories

$4 m$3.4 m$8.9 m$16 m

Current Assets

$113.4 m$122.3 m$251.4 m$307.2 m

PP&E

$1.2 m$763 k$6.4 m$6.2 m

Goodwill

$60.9 m$73 m

Total Assets

$137 m$141.6 m$457.2 m$520.9 m

Accounts Payable

$7.6 m$4.1 m$11.2 m$9.2 m

Current Liabilities

$42.6 m$33.8 m$88.1 m$32.4 m

Additional Paid-in Capital

$72.1 m$83.6 m$99.2 m$120.3 m

Retained Earnings

($27.7 m)($13.7 m)$19.6 m$38.1 m

Total Equity

$58.1 m$82.3 m$86.4 m$167.1 m

Financial Leverage

2.4 x1.7 x5.3 x3.1 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$6.4 m$13.1 m$33.4 m$18.5 m

Depreciation and Amortization

$1.5 m$10.6 m$45.7 m

Accounts Receivable

($4 m)($8.5 m)($19 m)

Inventories

($163 k)($1.4 m)($1.2 m)

Accounts Payable

$2.2 m($1.7 m)($2.8 m)

Cash From Operating Activities

($5.4 m)$27.5 m$18.6 m$8.3 m

Purchases of PP&E

($168 k)($3.6 m)($1.2 m)

Cash From Investing Activities

($13.9 m)($131.2 m)($1.8 m)

Interest Paid

$156 k$6 m$20 m

Sucampo Pharmaceuticals Market Value History

Sucampo Pharmaceuticals Online Presence

Sucampo Pharmaceuticals Company Life

You may also be interested in